Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Robert Belknap to Tuberculin Test

This is a "connection" page, showing publications Robert Belknap has written about Tuberculin Test.

 
Connection Strength
 
 
 
1.493
 
  1. Belknap R, Wall K, Reves R. What can the NHANES data tell us about the tuberculin skin test and the risk for active tuberculosis? Am J Respir Crit Care Med. 2008 Oct 15; 178(8):883-4; author reply 884.
    View in: PubMed
    Score: 0.299
  2. Gaensbauer J, Young J, Harasaki C, Aiona K, Belknap R, Haas MK. Interferon-Gamma Release Assay Testing in Children Younger Than 2 Years in a US-Based Health System. Pediatr Infect Dis J. 2020 09; 39(9):803-807.
    View in: PubMed
    Score: 0.170
  3. Venkatappa TK, Punnoose R, Katz DJ, Higgins MP, Banaei N, Graviss EA, Belknap RW, Ho CS. Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection. J Clin Microbiol. 2019 11; 57(11).
    View in: PubMed
    Score: 0.161
  4. Sosa LE, Njie GJ, Lobato MN, Bamrah Morris S, Buchta W, Casey ML, Goswami ND, Gruden M, Hurst BJ, Khan AR, Kuhar DT, Lewinsohn DM, Mathew TA, Mazurek GH, Reves R, Paulos L, Thanassi W, Will L, Belknap R. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019 May 17; 68(19):439-443.
    View in: PubMed
    Score: 0.156
  5. Chee CBE, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: Opportunities and challenges. Respirology. 2018 10; 23(10):893-900.
    View in: PubMed
    Score: 0.146
  6. De Groote MA, Higgins M, Hraha T, Wall K, Wilson ML, Sterling DG, Janjic N, Reves R, Ochsner UA, Belknap R. Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection. J Clin Microbiol. 2017 02; 55(2):391-402.
    View in: PubMed
    Score: 0.131
  7. Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, Wang Y, Cronin W, Hirsch-Moverman Y, Teeter LD, Parker M, Garrett DO, Daley CL. Interferon-? release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014 Jan 01; 189(1):77-87.
    View in: PubMed
    Score: 0.107
  8. Ayers T, Hill AN, Raykin J, Mohanty S, Belknap RW, Brostrom R, Khurana R, Lauzardo M, Miller TL, Narita M, Pettit AC, Pyan A, Salcedo KL, Polony A, Flood J. Comparison of Tuberculin Skin Testing and Interferon-? Release Assays in Predicting Tuberculosis Disease. JAMA Netw Open. 2024 04 01; 7(4):e244769.
    View in: PubMed
    Score: 0.055
  9. Zavala S, Winglee K, Ho CS, Pettit AC, Ahmed A, Katz DJ, Belknap RW, Stout JE. Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in People Born Outside the United States. Ann Am Thorac Soc. 2023 09; 20(9):1258-1266.
    View in: PubMed
    Score: 0.052
  10. Winglee K, Hill AN, Belknap R, Stout JE, Ayers TL. Variability of interferon-? release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. Clin Microbiol Infect. 2022 Jul; 28(7):1023.e1-1023.e7.
    View in: PubMed
    Score: 0.047
  11. Pettit AC, Stout JE, Belknap R, Benson CA, Séraphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS. Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021 10 05; 73(7):e2278-e2284.
    View in: PubMed
    Score: 0.046
  12. Feng PJ, Wu Y, Ho CS, Chinna L, Whelen AC, Largen A, Brostrom R, Reves R, Belknap R, Cattamanchi A, Banaei N. Impact of T-Cell Xtend on T-SPOT.TB Assay in High-Risk Individuals after Delayed Blood Sample Processing. J Clin Microbiol. 2021 04 20; 59(5).
    View in: PubMed
    Score: 0.045
  13. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med. 2020 03 01; 201(5):598-605.
    View in: PubMed
    Score: 0.041
  14. Gaensbauer J, Gonzales B, Belknap R, Wilson ML, O'Connor ME. Interferon-Gamma Release Assay-Based Screening for Pediatric Latent Tuberculosis Infection in an Urban Primary Care Network. J Pediatr. 2018 09; 200:202-209.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)